Evidence map›Paper›PMID 34686589›Full record

ArticleLupus science & medicine2021

Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus.

Erik W Anderson, Joanna Fishbein, Joseph Hong, Julien Roeser, Richard A Furie, Cynthia Aranow, Bruce T Volpe, Betty Diamond, Meggan Mackay

Open access · goldAbstract read
In one paragraph

Article in Lupus science & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Erik W AndersonInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA eanderson22@northwell.edu.ORCID 0000-0003-3154-9648
Joanna FishbeinInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Joseph HongInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Julien RoeserCharles River Laboratories, South San Francisco, California, USA.
Richard A FurieInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.ORCID 0000-0001-6712-1585
Cynthia AranowInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.ORCID 0000-0001-9299-0053
Bruce T VolpeInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Betty DiamondInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.ORCID 0000-0002-3250-3804
Meggan MackayInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.
Feinstein Institute for Medical Research · USCharles River Laboratories (Germany) · DE

Funding

The Monoclonal Antibody and Reagent CoreP01AI073693 · NIAID · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Cynthia Aranow · 2008 to 2026
$45.8M
NIAID NIH HHS P01 AI073693
6 · The paper itself

Abstract

objectivesInterferon-alpha, an important contributor to SLE pathogenesis, induces the enzyme indoleamine 2,3-dioxygenase in the kynurenine/tryptophan (KYN/TRP) pathway. This leads to a potentially neurotoxic imbalance in the KYN/TRP pathway metabolites, quinolinic acid (QA), an N-methyl D-aspartate glutamatergic receptor (NMDAR) agonist, and kynurenic acid (KA), an NMDAR antagonist. We determined whether QA/KA ratios associate with cognitive dysfunction (CD) and depression in SLE.

methodsThis cross-sectional study included 74 subjects with SLE and 74 healthy control (HC) subjects; all without history of neuropsychiatric disorders. Serum metabolite levels (KYN, TRP, QA, KA) were measured concurrently with assessments of cognition (Automated Neuropsychological Assessment Metrics (ANAM), 2×2 array), mood and pain, and compared between SLE and HC. Multivariable modelling in SLE was used to evaluate associations of metabolites with cognitive performance and depression.

resultsSerum KYN/TRP and QA/KA ratios were elevated in SLE versus HC (p<0.0001). SLE performed worse than HC on four of five ANAM tests (all p≤0.02) and the 2×2 array (p<0.01), and had higher depression scores (p<0.01). In SLE, elevated QA/KA ratios correlated with poor performance on Match to Sample (MTS), a working memory and visuospatial processing task (p<0.05). Subjects with SLE with elevated QA/KA ratios also had slightly higher odds of depression, but this did not reach significance (p=0.09). Multivariable modelling in SLE confirmed an association between QA/KA ratios and poor MTS performance when considering potentially confounding factors (p<0.05).

conclusionsElevated serum KYN/TRP and QA/KA ratios confirm KYN/TRP pathway activation in SLE. The novel association between increased QA/KA ratios and poor cognitive performance supports further study of this pathway as a potential biomarker or therapeutic target for SLE-mediated CD.

Indexed as

Cognitive DysfunctionLupus Erythematosus, SystemicCross-Sectional StudiesHumansKynurenineNeuropsychological TestsQuinolinic AcidTryptophanKynurenineQuinolinic AcidTryptophanautoimmunitycytokinesinflammationlupus erythematosussystemic

Identifiers

PMID34686589
PMCPMC8543639
OpenAlexW3207716266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.